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Background:  In adult inpatients with acute kidney injury (AKI), clinicians routinely 
order a renal ultrasound (RUS).  It is unclear how often this test provides 
clinically useful information.   
 
Specific Aims:  We aimed to develop a simple decision rule that will  
identify those patients with AKI who are at low risk of hydronephrosis (HN) on 
RUS, or HN requiring an intervention (HNRI; defined as nephrostomy tube or 
stent placement).  Using this classification scheme, we also aimed to evaluate 





Methods:  We conducted a cross-sectional study, divided into derivation and 
validation samples.  Our sample consisted of 997 U.S. adult inpatients who were 
admitted to Yale-New Haven Hospital (YNHH) from January 1, 2005 to May 1, 
2009, diagnosed with AKI, and received diagnostic RUS in the evaluation of their 
elevated Creatinine.  Pregnant women, renal transplant recipients, and patients 
with recently diagnosed HN were excluded.  Demographic and clinical 
characteristics were abstracted from the medical records, including pre-existing 
comorbidities, inpatient course (e.g. use of pressors) and exposures (e.g. 
contrast or nephrotoxic medications).  A multivariable logistic regression model  
was used to create risk strata for HN and HNRI; a separate sample was used for 
validation.  We assessed the presence of incidental findings on RUS for each 
stratum (i.e. other clinically useful findings other than presence of HN). In the 
validation sample, patients were classified according to their risk of HN; this 
system was assessed in terms of its sensitivity, specificity, negative predictive 
value (NPV), NNS, and cost of RUS evaluation per positive study.    
 
Results:  In the derivation sample of 200 patients, seven factors were found to be 
associated with HN: history of HN, recurrent urinary tract infections, diagnosis 
consistent with obstruction, non-black race; and absence of – exposure to 
nephrotoxic medications, congestive heart failure, or pre-renal status prior to AKI.  
Patients were assigned to the low risk group when 0-2 risk factors were present, 
medium risk group when 3 factors were present, and high risk group when 4 or 
 
 
more factors were present or when there was a documented history of HN.  
Among 797 patients in the validation sample (mean age of 65.6 years), 10.6% 
had HN and 3.3% had HNRI.  Of the 223 patients assigned to the low risk group, 
seven (3.1%) had HN and one (0.4%) had HNRI (223 patients needed to screen 
to find one HNRI).  In this group, there were no incidental findings on RUS 
unknown to the clinical team.  In the higher risk group, 15.7% had HN and 4.7% 
had HNRI. The NNS to find one case of HN in the low risk group is 32, or $6,371 
per positive study (at a cost of $200 per study).  For HNRI, the NNS for the low 
risk group in the same model was 223, at a cost of $44,600 per positive study.   
       
Conclusions:  In adult inpatients with acute kidney injury, specific factors can 
identify patients who are unlikely to have hydronephrosis, or hydronephrosis 
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 The problem of high healthcare spending in the U.S. is a familiar one in 
this year of healthcare reform: we pay more for our care than any other country 
and aren’t healthier as a result.  [1, 2]   The case for cost-control is persuasive – 
rising costs degrade employer-sponsored insurance, reduce access to care 
leaving more Americans without insurance, and displace spending on other 
societal priorities.  [3, 4]   Cost-control has received much attention from policy-
makers in this first year of the Obama administration, who have stressed the 
importance and cost-saving potential of comparative-effectiveness research, 
preventive care, disease management, and health information technology in the 
recent push for reform.  [5]   
 At the heart of the debate surrounding cost-control are two questions: how 
are we spending our healthcare dollars and what are we getting in return?  Much 
of the most relevant and frequently cited research that has helped answer these 
questions at a national level comes from the Dartmouth Atlas of Health Care.  [6]  
The Dartmouth group evaluates Medicare spending by “hospital referral region”, 
a unit of analysis which breaks down the nation according to patterns of use of 
local hospitals.  By considering utilization in this way, regional variation in 
spending and clinical outcomes can be assessed.   
 What the Dartmouth data show is marked variation in healthcare spending 
by geographic area.  In some areas, the results are staggering.  Between 1992 




Island and San Francisco was approximately one billion dollars.  [7]  These 
differences remain after adjustment for regional differences in patient health.  In 
the setting of this marked regional variation, much attention has been paid to 
finding out where the money is going.   
 One key area of focus has been the use of imaging services by 
physicians.  Expenses for high technology imaging, including magnetic 
resonance imaging (MRI), computed tomography (CT), and sonography have 
grown more than almost any type of health care service in recent years.  [8-10]  
According to a recent report from the Government Accountability Office (GAO), 
from 2000 to 2006, Medicare spending on radiology services under the physician 
fee schedule more than doubled.  [11]   
 Evidence from regional variation research suggests that much of this 
spending is unnecessary.  In the GAO report, substantial variation was noted in 
imaging utilization.  For example, in-office imaging spending per Medicare 
beneficiary varied from $62 in Vermont to $472 in Florida. [11] The Dartmouth 
data shows similar trends: compared to Medicare patients in the lowest-spending 
regions, patients in the highest-spending regions have more frequent physician 
visits and undergo more MRI procedures (21.9 vs. 16.6 per 100 beneficiaries) 
and CT scans (61.4 vs. 46.9 per 100). [7]  As previous studies have suggested 
that as high as 30% of imaging services may be inappropriate, marked variation 
in utilization by region raises the question of whether a large portion of radiology 




 One explanation that likely accounts for much of this marked variation is 
discretionary decision-making: how physicians decide to allocate diagnostic and 
therapeutic modalities in caring for their patients.  [13]  In hospital settings, these 
decisions are shared both by clinicians caring for patients and radiologists 
advising imaging choices.  Radiologists, for their part, have contributed 
significantly to the literature on evidence-based support of imaging decisions.  
For instance, the American College of Radiology (ACR) publishes 
comprehensive appropriateness criteria to inform decision-making surrounding 
specific clinical questions, such as the proper initial imaging of a palpable breast 
mass in a woman 30 years or older.  [14]  These guidelines are based on 
outcomes data as well as broad-based empiric consensus among physician 
committees and societies.  The ACR criteria have been increasingly utilized by 
both institutions and payers, including the largest private insurance company in 
the U.S., UnitedHealth Group.  [15]  When implemented, these guidelines have 
the potential for significant reductions in imaging use, with some studies reporting 
reductions of 40-50%.  [16]    
 Another important form of decision support that may improve resource 
utilization as well as clinical outcomes is the use of clinical decision rules (CDRs). 
[17]  Like appropriateness criteria, these algorithms are designed for specific 
clinical questions and help guide clinicians through diagnostic and management 
decisions.  However, CDRs go a step further, by allowing clinicians to use clinical 
factors to assess the likelihood of a particular result, diagnosis, or other outcome, 




can help determine the pretest probability of a diagnostic test, identify the most 
beneficial treatment modality, or predict a patient’s prognosis.  [18-21] Many 
have become commonplace in clinical medicine, helping clinicians decide when 
to treat sore throats, establishing the likelihood of pulmonary embolus, screening 
for common conditions that often go unnoticed such as alcohol abuse, and 
estimating risk of future conditions such as the development of delirium in 
hospitalized patients.  [22-25] 
 A number of high impact studies have produced CDRs that guide 
decision-making around imaging.  One important study examined the use of 
computed tomography (CT) of the head by clinicians before performing lumbar 
puncture for adult patients with suspected meningitis.  [26]  In this prospective 
study of 301 adults in the YNHH Emergency Department, clinical features such 
as a history of central nervous system disease or seizure within one week before 
presentation were found to be associated with an abnormal finding on CT.  Using 
these features, a subgroup of patients could be identified who were unlikely to 
have an abnormal CT result.  In principle, these patients could be managed 
without CT testing and thus avoid the unnecessary radiation exposure of the 
study and a prolonged stay in the emergency department. 
 Perhaps the best-known CDR in imaging decision support is the Ottawa 
Ankle Rule.  In the original study from which the rule was developed, 750 adults 
with acute ankle injuries were assessed for 32 standardized clinical variables, 
such as bony tenderness at pre-specified locations. [27]  These variables were 




ankle radiographic series.  In the main study, the two rules correctly predicted all 
significant fractures to achieve a sensitivity of 100%.  The “cut-point” was 
constructed to achieve as high a sensitivity as possible at the expense of a high 
specificity (40% in the main study) because the authors assumed that clinician 
use would be optimized if there was little concern about missing fractures without 
imaging.  After a second large study to refine these rules, they were 
prospectively validated in two other emergency departments and remained 100% 
sensitive. [28]      
 Though CDRs are common and continuously developed, there remain 
important and frequently encountered clinical questions for which little decision 
support exists.  Acute kidney injury (AKI) is one major example.  AKI is a 
common problem in hospitalized patients, with an incidence that has increased 
from approximately 10 to 25 per 1000 discharges over the last 15 years. [29]  
Conceptually defined as an abrupt decline in renal function, AKI is significantly 
associated with increased mortality. [30]  Early epidemiologic work assessed 
hospital-acquired disease through cohort studies.  In one of the first prospective 
cohort studies of AKI, published in 1983, hospital-acquired disease was most 
often caused by decreased renal perfusion (42%), with less likely precipitating 
factors including major surgery, contrast exposure, and aminoglycoside use.  [31]  
These findings were replicated in more recent cohorts, with compromises in renal 
perfusion remaining the most common causes (including congestive heart failure, 
cardiac arrest, and volume contraction) [32].  Multi-center cohort studies and 




[33, 34]    In one recent study which included both hospital- and community-
acquired AKI, the most common cause of acute tubular necrosis (45%) followed 
by pre-renal disease (21%, defined as a decline in renal function rapidly reversed 
by fluid administration) and urinary tract obstruction (10%).   [33]  
 One of the diagnostic modalities used in the initial evaluation of AKI is a 
renal (or retroperitoneal) ultrasound (RUS).  It is often ordered to exclude an 
obstructive etiology.  [35, 36]   If diagnosed, patients with an obstruction may 
require further interventions that can treat the underlying cause of the AKI.  
However, as described above, the vast majority of AKI is not caused by 
obstruction. [29] In fact, hydronephrosis (HN), the evidence of obstruction on 
imaging, is a rare finding in patients with AKI, present on between one and 10% 
of ultrasound studies ordered in this setting. [33, 37-39]  As a result, RUS does 
not change clinical management in the majority of AKI patients who undergo the 
test.  Additionally, it has been suggested that obtaining a RUS might yield 
additional information that is clinically useful, yet little is known about how 
frequently this occurs.  [39, 40] 
       Because RUS is relatively expensive, costing approximately $200 per study, 
targeting RUS evaluation towards patients with a higher risk of HN would not only 
be clinically useful, but could potentially conserve resources. [41]  This type of 
patient-centered decision making, and targeting of testing towards those most 
likely to benefit, has been recently recommended by the Institute of Medicine and 




Further information is needed in order to stratify patients with AKI 
according to the likelihood that a RUS will yield clinically meaningful results. We 
sought to create a stratification system that would help clinicians ascertain a 
patient’s risk of renal obstruction among those with AKI. This approach would 
improve the pre-test probability of a positive finding on RUS, and hence the 
likelihood of influencing the post-test management of patients most likely to 
benefit.  Specifically, we designed and validated a decision rule that would 
identify those patients at low risk of obstruction, as well as those patients at low 
risk for an obstruction requiring surgical intervention. As a secondary analysis, 
we evaluated the additional value of RUS by assessing the presence of other 
non-HN, but clinically useful findings.  Finally, we assessed RUS utilization at 






 Our hypothesis is that clinical and demographic factors can be used to 
develop a decision rule to classify AKI patients according to their risk of HN.  
Moreover, for patients at low risk of HN, RUS would offer little value to the 





1.  To assess the association between baseline patient characteristics and: 
a.  HN on renal ultrasound 
b.  HN on renal ultrasound that required an intervention;  
2.  To develop a simple, transportable decision rule (based on demographic and 
clinical factors found to be associated with HN in Aim 1) for identifying patients 
with AKI who are unlikely to benefit from a RUS; 
3.  To validate the decision rule in a separate group of patients; 
4.  To determine the prevalence of other non-HN findings on RUS according to 
risk group; 








Adam Licurse contributed to each stage of this study, including conception and 
design, acquisition of data, analysis and interpretation of data, statistical analysis, 
and drafting of the thesis. 
 
Study Design 
 We conducted a cross-sectional study of hospitalized patients with AKI, 
using separate derivation and validation samples.  For patients with AKI who met 
inclusion criteria, we abstracted demographic and clinical data, as well as the 
results of their RUS study.   A derivation sample was analyzed using the 
presence of HN on RUS as the dependent variable of interest.  Strata were 
created based on presence of risk factors associated with HN in the derivation 
sample. A validation sample was developed using all RUS studies performed 
over a one-year period, and the presence of HN and HNRI was assessed in each 
risk group.  This study was approved by the Yale Human Investigation 
Committee in April of 2008.   
 
Patients 
A two-step approach was used to create samples of inpatients with AKI 
who undergo RUS.  First, patients were identified by searching the YNHH 
imaging database for RUS studies performed on hospitalized adults (> 18 years 




AKI was defined by a list of terms we piloted in a three-month analysis of RUS 
studies, including “hydronephrosis,” “creatinine,” and “arf” (for complete list, see 
appendix).  The strategy was designed to create a sample of patients who 
received an RUS in the workup of elevated Creatinine, rather than simply any 
indication (e.g. we excluded studies ordered to assess stone disease without 
concern for compromised renal function).  On the other hand, only those patients 
who received a RUS were included, rather than all AKI patients, in order to 
construct an enriched sample of patients whose clinicians were concerned 
enough about an obstructive etiology to order a RUS (i.e. patients at such low 
risk for obstruction that they never received a RUS were not included).   
Second, patients were excluded who did not meet the definition of AKI: an 
absolute rise in serum creatinine (CR) of 0.3 mg/dL from baseline, based on the 
peak serum CR during an inpatient admission.  Though AKI is a complex 
disorder with a changing definition, we operationalized it according to a recent 
recommendation from the Acute Kidney Injury Network, whose members 
represent key societies in nephrology.  [43]  Baseline serum CR was defined as 
the lowest value in the three months prior to admission (if unavailable, then in 
order: the lowest value 12 months prior to admission, the baseline value 
described in the admission note, and finally the lowest value during the current 
admission).  Additional exclusion criteria included pregnancy, history of a renal 
transplant, and a previous diagnosis of HN within the 30 days prior to the study 
date (these were considered follow-up studies, rather than primary diagnostic 




Separate derivation and validation samples were constructed from those 
eligible studies (Figure 1).  In the derivation sample, 100 studies with HN on RUS 
and 100 randomly selected normal studies were included.  This approach was 
used to maximize power in the derivation sample, as HN is a relatively rare 
finding.  In the validation sample, all eligible studies from January 1, 2008 to May 
1, 2009 were included.  In both derivation and validation, one study per patient 
was included.   
 
Figure 1. Study flow diagram







Assessment of Risk Factors and Outcomes 
 We chose candidate risk factors based on clinical relevance and 
description in the salient medical literature. [38-40]  All data was abstracted from 
medical records (discharge summaries and clinical notes) by four trained 
reviewers.  The abstraction form was piloted and refined on a sample of 50 
patients before use in the study sample.  Inter-observer agreement was 
calculated for 10% of the derivation sample, and was found to be 95% overall.  
Chart reviewers were blinded to the RUS result for each patient.  [19, 44]  
Demographic data included race, age, and sex.  Clinical data was abstracted in 
two general categories: those factors predisposing a patient to obstructive AKI, 
such as history of abdominal or pelvic cancer, and factors making another 
etiology more likely (e.g. hemodynamic instability or pressor use for pre-renal AKI 
and acute tubular necrosis, or exposure to intra-arterial contrast for contrast-
induced nephropathy).    Other variables included laboratory data (e.g. granular 
casts on urinalysis) or certain inpatient exposures (e.g. radiographic contrast).  
Clinical variables were only coded if they were available and known by the 
clinical team prior to the maximum serum CR value and RUS date (for full list of 
variables, see Table 1). 
 All data were constructed as categorical variables, except for the mean 
rise in CR, age and white blood cell count, which were constructed as continuous 
variables.  Age and white blood cell count were then dichotomized based on 




angiography or cardiac catheterization, owing to their association with contrast-
induced nephropathy. [45, 46]  Hospital-acquired AKI was defined as AKI for 
which the maximum serum CR occurred greater than two days after the date of 
admission. One variable was coded two ways.  In our primary model “No history 
of pre-renal status prior to AKI” only included history of sepsis during current 
admission or use of pressors, while in a second model (designed for sensitivity 
analysis), this variable also included history of hypotension prior to the onset of 
AKI, defined as at least two consecutive episodes of systolic blood pressure 
below 80 mm Hg or diastolic pressure below 60 mm Hg. 
 The study outcomes were HN, and HN requiring intervention (HNRI).  Any 
RUS report which described “hydronephrosis” in the findings section was 
considered an outcome event.  HNRI was defined as a RUS-diagnosed HN 
followed by either a urologic stent or nephrostomy tube placement performed 
after the RUS date.  As a secondary analysis, we also assessed the prevalence 
of incidental non-HN findings on RUS.  These were defined as anatomic 
abnormalities or masses described in the RUS report we included in our study 
(for a list of search terms, see appendix).  To determine whether these findings 
were previously known to the clinical team, we searched for prior documentation 
in the patient’s chart or imaging history, dating back to the beginning of the 








 The association between candidate risk factors and presence of HN on 
RUS was initially assessed for the derivation sample using bivariate logistic 
regression analysis .  Clinically relevant variables with a p-value < 0.1 from the 
bivariate analysis were used to generate a logistic regression model in the 
derivation sample.  A “history of HN” was defined as a documented history of HN 
in the medical record or any previous imagining history of HN in the prior two 
years.  In multivariable logistic regression, variables were removed in order of 
decreasing p-value and the model’s quality was assessed at each step.  We 
calculated the AIC and C-statistic for each iteration.  Stepwise regression was 
continued until the model’s quality was optimized (according to the C-statistic and 
AIC).   We selected the model with the best accuracy (i.e. discrimination), and 
applied it to the validation sample.  For a sensitivity analysis, we evaluated a 
second model, which differed from the main model only in the definition of a 
single clinical variable (“pre-renal status”) which showed poorer discrimination 
between HN and normal patients, but had a lower AIC than the primary model.     
 A risk score was developed based on the individual odds ratio (OR) of 
each variable in the model.  As all but one risk factor had similar ORs, they were 
each awarded a risk point of one.  Any patient with a known history of HN was 
assigned a priori to the high risk group, as these patients were considered most 
likely to need a RUS in the setting of AKI.  In fact, this variable was the only one 
with an OR greatly different from the others (approximately 11, compared to 2-3).  




on the prevalence of HN among patients with each risk score.  This stratification 
was then applied to a validation sample, the necessary size of which was 
calculated to be 800 patients.  This sample size would provide 80% power in the 
validation sample to detect a prevalence of HNRI in the low risk group of 0.3-
0.5%.  
 Finally, we calculated the number needed to screen (NNS) to find one 
case of HN or HNRI for each risk group (i.e. the total number of patients in each 
group divided by number of outcome events).  To estimate cost associated with a 
positive finding, we multiplied the NNS by the approximate cost per study 









Derivation sample and bivariate analysis 
 Our derivation sample consisted of 100 patients with HN and 100 patients 
without HN.  The mean age 65.6 years, 56.5% were male and 25.5% were black; none 
of these characteristics was significantly related to HN status.  Overall, HN patients 
were more likely to have a previous diagnosis of HN (on RUS or abdominal/pelvic CT; 
3% of normal patients vs. 28% of HN patients, p < 0.001), a history of abdominal or 
pelvic cancer (14% vs. 38%, p <0.001), previous pelvic surgery (10% vs. 19%, p=0.11), 
a single functional kidney (1% vs. 6%, p=0.054), or hematuria (4% vs. 13%, p=0.023) 
during the selected admission (Table1).  A past history of urologic dilatation on imaging 
not considered HN, described as “pelvicaliectasis” or “caliectasis”, was not significant, 
nor was an imaging history of anatomic abnormalities, stones, masses, or cysts.   
 Conversely, patients with a normal RUS were more likely to have granular casts 
on urinalysis (28% vs. 18%, p=0.09), a white blood cell count greater than 16,000 
cells/mm3 (48% vs. 24%, <0.001), a history of congestive heart failure (22% vs. 13%, 
p=0.094), documented hypotension during the current admission (55% vs. 39%, 
p=0.011); or exposure to either aspirin (>81mg/day), a diuretic or ACE-inhibitor, or 
intravenous vancomycin during the current admission (63% vs. 39%, p=0.001).  Use of 







  Table 1.  Patient characteristics and HN status, derivation sample 
Patients with HN, % 
(n=100) 










  Demographics 
Age <55 28 17 14 3 0.063 
Race, non-black  69 80 59 21 0.074 
Male sex 56 56 42 14 1.00 
  Laboratory data 
Granular casts on urinalysis (3 days 
before or after maximum serum CR 
value) 
28 18 16 2 0.093 




48 24 15 9 <0.001 
Mean absolute rise in serum CR 
(md/dL) 
1.97 2.67 4.05 2.23 0.11 
Urine output (<500 ml/day) 11 12 7 5 0.76 
Clinical history consistent with obstructive AKI 
Documented history of HN 1 9 4 5 0.0097 
History of HN on previous imaging 
(CT or RUS) 
3 28 16 12 <0.001 
Abdominal or pelvic Cancer 14 38 24 14 <0.001 
Recurrent UTIs (mentioned by name in 
chart, or > 2 in year prior to current 




Recurrent UTIs (mentioned by name in 
chart, or > 2 in year prior to current 
admission) 
6 19 15 4 <0.001 
BPH 10 14 13 1 0.38 
One functional kidney 1 6 4 2 0.054 
Neurogenic bladder 0 7 6 1 0.0071 
Pelvic surgery 11 19 16 3 0.11 
Flank pain  2 6 5 1 0.15 
Hematuria  4 13 10 3 0.023 
Clinical history consistent with non-obstructive AKI 
Congestive heart failure 22 13 9 4 0.094 
Hypotension (> 2 measurements of 
either SBP<100 or DBP<80 within 5 
days prior to maximum serum CR 
level) 
55 39 30 9 0.011 
Sepsis (mentioned directly in chart) 19 10 7 3 0.071 
Cirrhosis 5 3 0 0 0.47 
Hypertension 68 61 45 16 0.30 
Diabetes 45 33 27 6 0.082 
Chronic kidney disease 34 28 18 10 0.36 
Hospital-acquired AKI (AKI for which 
the maximum serum CR value was 
reached  > 2 days after admission date) 
46 35 27 8 0.005 
 Medications and nephrotoxic exposures (within 10 days prior to maximum serum CR value) 
IV Contrast (angiography or cardiac 
catheterization) 
1 6 6 0 0.054 
Aspirin > 81 mg/day 13 5 5 0 0.048 







Derivation of classification schemes 
The final model was selected based on its high accuracy and low AIC (Table 2).  
It consists of 7 variables: history of HN (high risk group), recurrent urinary tract 
infections (1 point), diagnosis consistent with possible obstruction (1 point), non-black 
race (1 point); and absence of the following – exposure to inpatient nephrotoxic 
medications (1 point), congestive heart failure (1 point), or pre-renal status prior to AKI 
(1 point).  This system was applied to the derivation sample and the prevalence of HN 
was assessed for each risk score. Three distinct risk groups emerged: low (<2 points, 1-






Diuretic or ACE-inhibitor 42 20 14 6 <0.001 
Pressor 18 6 4 2 0.024 
Vancomycin 44 25 20 5 0.005 
Any IV antibiotic 59 55 51 4 0.57 
a
value for pairwise comparison of patients with vs. patients without HN 
 
NNS = number needed to screen, HN = hydronephrosis, CT = computed tomography, RUS = renal ultrasound, UTI = urinary tract infection   
BPH = benign prostatic hyperplasia, SBP = systolic blood pressure (DBP = diastolic), CR = creatinine  











Adjusted Odds Ratio (95% CI, adjusted p-value) 
 Model 1 (primary) Model 2 
Race  
  Non-black 53.7 2.1 (0.1-4.4, 0.060) 2.2 (1.0-4.6, 0.046) 
  Black 39.2 1.0 1.0 
History of recurrent urinary tract infections 
  Yes 76.0 2.7 (0.8-8.5, 0.10) 2.3 (.7-7.1, 0.16) 
  No 46.3 1.0 1.0 
Diagnosis consistent with possible obstruction
a 
  Yes 67.4 2.4 (1.2-4.6, 0.010) 2.4 (1.2-4.7, 0.009) 
  No 36.0 1.0 1.0 
History of HN
b 
  Yes 90.3 11.1 (3.0-41.3, <0.001) 11.7 (3.0-45.2, <0.001) 
  No 42.6 1.0 1.0 
History of CHF 
  No 52.7 2.1 (0.8-5.2, 0.12) 2.0 (0.8-5.0, 0.14) 
  Yes 37.1 1.0 1.0 
History of pre-renal status prior to AKI (use of pressors or history of sepsis) 
  No 53.0 2.3 (0.9-6.2, 0.10)  
  Yes 35.3 1.0   
History of pre-renal status prior to AKI (use of pressors, history of sepsis, or 
hypotension) 
  No 60.2  2.1 (0.9-3.6, 0.041) 
  Yes 40.2  1.0 
20
Exposure to nephrotoxic medications prior to AKIc
No 62.2 2.1 (1.0-3.85, 0.053) 1.8 (0.9-3.6, 0.092)
Yes 38.2 1.0 1.0




Diagnosis consistent with possible obstruction = benign prostatic hyperplasia, abdominal or pelvic cancer,
neurogenic bladder, single functional kidney, or previous pelvic surgery.
b
History of HN = documented history of HN in the medical record or any previous imagining history of HN in the two
years prior to the current RUS.
c
Nephrotoxic medications = aspirin (>81mg/day), diuretic, ACE-inhibitor, or intravenous vancomycin.
HN = hydronephrosis , CHF = congestive heart failure, AKI = acute kidney injury





Validation of classification schemes 
 Our validation sample consisted of 797 patients (mean age=65.6).  Of 
these, 54.6% were male and 22.8% were black.  Overall, 10.6% had HN, of 
which 31.7% required an intervention (3.3% of total sample).   
 Two models were used in this sample.  Model 1 was our primary model, 
and differed from model 2 only in its definition of pre-renal status.  It was more 
sensitive for HN, but included fewer patients in the low risk group (i.e. less 
specific).  Out of 797 patients, 223 (27.8%) were assigned to the low risk group, 
of whom 3.1% had HN [1 patient, or 0.4% (0.01-2.5) had HNRI].  The prevalence 
of HN in the middle risk group was 10.7%, and 16.1% in the high risk group 




Figure 2. Prevalence of HN and HNRI in validation sample 
Figure 2: Prevalence of patients with HN and HNRI in the validation sample (n=797). 
 
HN = hydronephrosis 







 When dichotomized to low risk vs. all others, the NPV of the stratification was 
96.9% (95.7-98.1) for HN and 91.8% (89.9-93.7) sensitive, with a negative likelihood 
ratio (NLR) of 0.27.  When the outcome was HNRI, the NPV increased to 99.6 (99.1-
100.0) and the sensitivity increased to 96.3 (94.9-97.6), with a NLR of 0.13 (Tables 3, 








 Model 1 (primary), no. of 
patients 
Model 2, no. of patients 
Model 
classification 
HN Normal HN Normal 
Low risk 7 216 17 314 
Medium or high 
risk 




96.9 (95.7-98.1) 94.9 (93.3-96.4) 
Sensitivity 91.8 (89.9-93.7) 80.0 (77.2-82.8) 













HN = hydronephrosis 












 Model 1, no. of patients Model 2, no. of patients 
Model 
classification 
HNRI Normal HNRI Normal 
Low risk 1 222 1 330 
Medium or high 
risk 




99.6 (99.1-100.0) 99.7 (99.3-100.1) 
Sensitivity 96.3 (94.9-97.6) 96.3 (94.9-97.6) 





HN in low risk 
group 
0.4 (0.01-2.5) 0.3 (0.008-1.7) 
HN = hydronephrosis 






 We assessed the presence of incidental findings on RUS, other than 
presence of HN (e.g. masses, anatomic abnormalities) in the entire validation 
sample.  Among the 797 patients, there were eight incidental findings (1%) 
unknown to the clinical team: two horseshoe kidneys, four extra-renal pelvises, 
and two complex cysts. Of these, none were found in patients in the low risk 
group. 
 Model 2 was less sensitive for HN, but more specific.  In the low risk group 
there were 331 (41.5%) patients, of whom 5.1% had HN (1 patient had HNRI, or 
0.3%).  The NPV for HN was 94.9 (93.3-96.4) [99.7% (99.3-100.1) for HNRI], 
with a sensitivity of 80.0% (77.2-82.8) [96.3% (94.9-97.6) for HNRI] and a NLR of 
0.45 (0.09 for HNRI).   
 
Number needed to screen and cost savings estimate  
 The NNS to find one case of HN in the low risk group for model 1 is 32; 
compared to HNRI, which required an NNS of 223 (Figure 3).  If no RUS studies 
were ordered for low-risk patients, Models 1 and 2 would permit reduced 
utilization of 27.8% and 41.5%, respectively, of RUS studies.  At YNNH in 2008, 
approximately 700 RUS studies were performed in the setting of AKI on adult 
inpatients who met our inclusion criteria; 30% of these patients would be in the 
low risk group.  At an approximate cost of $200 per study, a 30% reduction in 




find one case of HN in the low risk group for model 1 cost $6,371 per positive 
study; for HNRI in the same model, the cost is $44,600 per positive study.   
 
 
Figure 3. Number needed to screen and cost in validation sample 
Figure 3:  Number needed to screen (NNS) and cost per positive result of renal ultrasound evaluation, according to risk group.  NNS = 
number of outcome events (HN or HNRI) / number of patients risk group.  Cost  = NNS (HN or HNRI) x $200 (approximate cost of 
ultrasound study). 
 
NNS = number needed to screen 
HN = hydronephrosis 








 In this retrospective study, we found that approximately 10% of patients who had 
RUS ordered in the setting of AKI had HN on RUS, and 3% had HNRI.  This prevalence 
estimate of HN is similar to previous studies. [33, 37-39]  We also derived and validated 
a decision rule to stratify inpatients with acute kidney injury by risk of having HN.  It is 
based entirely on common clinical information and can be easily applied, as 
recommended by reviews of methodological standards.  [18]  Our primary model was 
91.8% sensitive and had a NPV of 96.9% for HN.  To our knowledge, no such decision 
model exists in the literature. [38-40]   
 In addition to considering all cases of HN, we also assessed those which 
required an intervention (HNRI). It is these cases which are most important to identify, 
since they represent patients for whom a renal ultrasound affected their management.  
Our primary model was highly sensitive for HNRI (96.3%) with an NPV of 99.6%.  We 
defined our outcome HNRI as an acute surgical intervention most likely to be performed 
in the setting of HN, which 27 (31.8%) of the HN patients received in our validation 
sample. Each model had a negative likelihood ratio of near 0.1 for HNRI, a value which 
affects the pre-test probability of a positive finding to a large degree. [47]  There were 
other interventions performed on the HN patients, but these were less likely to be a 
direct result of finding obstruction on RUS: 60% of patients received a Urology consult, 
13% had a Foley placed, 2% had a cystoscopy, and 1% had lithotripsy performed (all 
performed after the RUS study).   Our model stratified all but one of the 27 HNRI 




assigned the same HNRI patient to the low risk group, a woman admitted with urosepsis 
and a history of a colectomy, nephrolithiasis, and a CT consistent with cirrhosis, who 
was diagnosed with hepatocellular carcinoma after the time of the RUS (beyond our 
window of analysis, which ended at the time of the RUS study). 
We also considered the value of RUS in terms of its ability to reveal clinically 
useful information other than the presence of HN.  Though the primary reason a 
clinician orders a RUS is to identify an obstructive etiology, there are other incidental 
findings that may be important to discover, including cysts, masses, or anatomic 
abnormalities.  In our validation sample of nearly 800 patients, there were no previously 
unknown incidental findings found in patients the low risk group. For many patients, the 
test result was not important enough to even be noted in the medical record.  In the low 
risk groups of both models there were 20 unique HN patients, of whom 19 did not 
receive an intervention. In five of these 19 cases, there was no mention of the RUS 
result in the patient’s progress notes.   For another seven, the result was not mentioned 
in their discharge summaries.  
 The evaluation of AKI is a nuanced process, one that likely requires clinical 
judgment not currently captured by our model.  We were not able to include all possible 
risk factors for obstruction, either to maintain model parsimony or because of a lack of 
statistical evidence (i.e. the variables were clearly not associated with HN in derivation), 
or both.  However, as with the one HNRI patient in the low risk group, there are likely 
risk factors not included in this model that should be incorporated into clinical decision-
making (or explicitly included by future refinements of this rule).  Since as many as 40% 




room for studies to be ordered for patients whose risk of obstruction is likely higher than 
calculated, while still markedly decreasing over-utilization. Patients who are at higher 
risk for obstruction according to this model should always receive sonographic 
evaluation, while the vast majority of the patients at low risk should not.       
 The cost savings we estimate are substantial.  To find one case of HNRI among 
low risk patients, we estimate that approximately $45,000 needs to be spent on RUS 
studies.    Moreover, this analysis was conservative.  We did not take into account all 
the potential savings of improved RUS utilization, such as the effect on length of 
hospitalization. As unnecessary diagnostic imaging contributes significantly to rising 
healthcare costs, this rule may lead to significant potential savings for healthcare 
institutions and payers. [48-50]  By establishing evidence-based guidelines, the marked 
geographic variation in spending on imaging may also be improved. [11, 13, 51] 
 One likely objection against this recommendation of selective RUS use is that 
ultrasound will still need to be ordered, regardless of a patient’s risk of obstruction, 
under certain clinical circumstances.  For instance, for those patients whose serum 
creatinine continues to rise after intravenous hydration and removal of nephrotoxic 
medications.  In these situations, a RUS evaluation should likely be undertaken.  
However, anecdotal experience suggests that many studies are not strictly ordered in 
this setting after an attempt at management has been made, but rather as part of an 
initial work-up of increased creatinine.  Indeed, for many of the patients included in our 
study, a RUS was ordered at the first sign of AKI, often concurrently or prior to the 




least, causes clinicians to delay ordering a RUS until their patients’ AKI persists in the 
face of medical management, the utilization of RUS will still be markedly improved. 
  Four previous studies have explored the association between clinical factors and 
presence of HN on RUS.  [38-40, 52]  In two older studies, the prevalence of HN was 
characterized in cohorts of hospitalized patients.  One of these studies excluded 
patients with known risk factors for HN, and the other stratified HN by severity of 
obstruction without assessing risk factors.  [38, 39]  In one recent study, 2854 patients 
underwent RUS evaluation over a three-year period, of whom 1.6% were found to have 
an obstructive etiology.  Obstruction was associated with male sex, age over 65, history 
of BPH, or history of nephrolithiasis.  [52]   In a similar study from 1988, 394 patients 
with acute kidney were assessed for a short list of risk factors determined a priori, 
including history of pelvic or abdominal cancer and previous pelvic surgery, and placed 
patients in one of two risk groups if any factor was present.   
 This work builds on the existing literature in a number of important ways.  First, 
we employed a recently recommended definition of AKI and use it as an exclusion 
criterion.  By doing so, we created a sample which we believe accurately represents a 
group of hospitalized patients on whom clinicians would order RUS studies.  Previous 
studies used much older definitions of acute renal failure, or simply considered all cases 
of RUS studies without limiting by reason for ordering.  Second, by creating a large 
number of demographic and clinical variables and assessing their independent 
association with HN, we were able to develop a decision rule that accurately stratified 
patients according to risk of HN.  No other study devised such a rule or used uni- or 




is the only study to validate a risk stratification system in a separate sample of patients.  
By doing so, we were able to increase the external validity of our rule, and assess it 
according to a number of important criteria, including its characteristics as a diagnostic 
test (i.e. sensitivity and NPV), and as well as its effectiveness, in terms of NNS.  Finally, 
we attempt a preliminary cost-savings analysis if our rule were implemented, a further 
step not taken by previous studies. 
 Once a CDR like ours is derived, it must be validated and refined to ensure its 
reliability and accuracy.  However, CDR use requires the time and energy of clinicians, 
so if implementation is not practical then systemic use will likely not be achieved.  
Studies assessing the impact of these rules in clinical practice (i.e. impact analysis) are 
a critical step towards widespread adoption.  Unfortunately, these studies are often not 
performed so little is known about many of the CDRs that have been developed.  [19]  
In the case of the Ottawa ankle rules, an impact analysis study used an implemented 
strategy to assess the effect of the rule on actual practice.  The intervention was a 
practical one: the rule was introduced at a general staff meeting, summarized and 
distributed in the form of pocket cards, posted through the emergency department, and 
included along with a pre-printed data collection form in each chart.  Compared to the 
control group, there was a 20% reduction in foot and ankle imaging without a single 
missed fracture leading to an adverse outcome.  Thus, a positive resource utilization 
was demonstrated with adverse clinical outcomes. [53]   
 However, implementation is often a significant challenge.  Studies suggest that 
systemic adoption may require local, effective, and proven implementation strategies to 




following practice guidelines, the most common reasons for non-use were lack of 
familiarity and awareness, and the presence of external barriers, including guideline-
related (i.e. rule was cumbersome), patient-related (i.e. rule was difficult to apply to 
individual patients or to reconcile with their wishes), and environmental (i.e. lack of time 
or support from staff, or reimbursement concerns).  [56] 
 One strategy that may improve the odds of successful implementation is the use 
of healthcare information technology in decision support.  As electronic medical records 
become more prevalent, CDRs can be incorporated into digital order entry systems and 
can prompt physicians to follow the rule when appropriate.  [57, 58]   In one study, a 
computerized physician order entry system was used to improve medication ordering 
and reduce adverse drug events.  [59]  The system performed drug-allergy checking, 
drug-drug interaction checking, and drug-laboratory checking and, together with a team-
based intervention, resulted in a 55% reduction in serious medical errors.  For our 
decision rule, a prompt could appear in a hospital’s order entry system asking clinicians 
to enter in their reason for ordering an RUS.  If the reason matched with a list 
representing words and phrases consistent with AKI, the clinician could be asked to 
input the information contained in our rule before completing the order and, if 
appropriate, may be advised to consider delaying sonographic evaluation.  As a key 
focus of the Obama administration’s efforts in health reform is the improvement and 
dissemination of technology in healthcare settings, these types of order-entry systems 
may play an increasingly important role in evidence-based care.  [5]   
 Another likely necessary step towards improving imaging utilization is increased 




was a history of HN, either as documented in the medical chart or seen on previous 
imaging.  However, in many of these patients with HN on previous imaging there was no 
documentation in the chart, likely indicating that the clinical team was unaware of the 
patient’s previous HN status.  As more evidence becomes available to guide clinical 
decision-making, both in the form of appropriateness criteria and CDRs, conversations 
between radiologists and clinicians will be increasingly more necessary.  In fact, early 
studies have shown that this type of communication leads to more informed decision-
making.  In two, direct consultation between clinicians and radiologists resulted in a 
substantial decrease in utilization of costly tests such as ultrasound and CT. [60, 61]  
However, this effect was not reproduced in a more recent randomized-controlled trial.  
[62]      
Our study has limitations.  The decision rule was derived and validated in a 
retrospective fashion in the same institution.  Future refinement and validation of the 
model should be pursued in prospective studies in other patient populations.  In 
addition, our study population represents only those patients who received a RUS while 
admitted.  As such, our sample likely represents a population enriched with obstruction 
(i.e. those patients at such low risk of obstruction who never received a RUS were not 
included).  Therefore, the inclusion of all patients admitted with AKI, not just those with 
AKI who received a RUS, would likely skew our HN prevalence data downward (and 
improve the NPV of our model). 
We have derived and validated a decision rule to help clinicians identify those 
patients at low risk of obstruction on ultrasound, and specifically those patients whose 




these models may allow clinicians to both order ultrasound studies for those patients at 
high risk for obstruction, and delay or decide not to order a study on the roughly one-
third of patients at low risk.  As more attention is paid to the cost-effectiveness of 
diagnostic modalities, prioritizing testing for those at higher risk of abnormal findings will 
result in more informed diagnostic approaches.  For inpatients with AKI, directing RUS 
studies towards those at greater risk of obstruction will both aid clinical decision-making 






To find RUS studies, the YNNH imagining database was queried for these words and 
phrases:  “creatinine” or “cr” (when used as an abbreviation), “renal failure,” “stone,” 
“nephrolithiasis,” “flank pain,” “arf,” “obstruction,” “hydronephrosis,” and “retention. 
 
Incidental findings were found by searching the radiologist’s report text for these words: 
“solitary” or “single” (kidney), “extra-renal” or “double” (pelvis), “complex” (cyst),  
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